Loading
A phase 1 trial of SC-101 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.
Study SC-101 in Subjects With Advanced Malignancies is a phase 1 interventional study registered as NCT06220838 by Tianjin ConjuStar Biologics Co., Ltd., with 100 participants planned, started 2024-02-02. Conditions recorded: Advanced Solid Tumor. Interventions recorded: SC-101.
Shares SC-101, ConjuStar Biologics and the tag pipeline.
Shares ConjuStar Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares ConjuStar Biologics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/